Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Genetic association and stress mediated down-regulation in trabecular meshwork implicates MPP7 as a novel candidate gene in primary open angle glaucoma.

Vishal M, Sharma A, Kaurani L, Alfano G, Mookherjee S, Narta K, Agrawal J, Bhattacharya I, Roychoudhury S, Ray J, Waseem NH, Bhattacharya SS, Basu A, Sen A, Ray K, Mukhopadhyay A.

BMC Med Genomics. 2016 Mar 22;9:15. doi: 10.1186/s12920-016-0177-6.

2.

Primary care physicians' role perception and self-reported performance in glaucoma care: a survey study.

Rotshtein A, Karkabi K, Geyer O, Cohen Castel O.

BMC Res Notes. 2015 Dec 12;8:776. doi: 10.1186/s13104-015-1770-z.

3.

Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.

Oddone F, Rossetti L, Tanga L, Berardo F, Ferrazza M, Michelessi M, Roberti G, Manni G, Centofanti M.

PLoS One. 2015 Oct 20;10(10):e0140601. doi: 10.1371/journal.pone.0140601. eCollection 2015.

4.

Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial.

Rossetti L, Sacchi M, Karabatsas CH, Topouzis F, Vetrugno M, Centofanti M, Boehm A, Vorwerk C, Goldblum D, Fogagnolo P.

BMC Ophthalmol. 2015 Jan 22;15:7. doi: 10.1186/1471-2415-15-7.

5.

Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting.

Cohen Castel O, Keinan-Boker L, Geyer O, Milman U, Karkabi K.

Fam Pract. 2014 Aug;31(4):453-61. doi: 10.1093/fampra/cmu031. Epub 2014 Jun 12.

6.

Clinical characteristics and current treatment of glaucoma.

Cohen LP, Pasquale LR.

Cold Spring Harb Perspect Med. 2014 Jun 2;4(6). pii: a017236. doi: 10.1101/cshperspect.a017236. Review.

7.

Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis.

Cheng JW, Xi GL, Wei RL, Cai JP, Li Y.

Curr Ther Res Clin Exp. 2009 Aug;70(4):335-50. doi: 10.1016/j.curtheres.2009.08.006. Review.

8.

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.

Figus M, Nardi M, Piaggi P, Sartini M, Guidi G, Martini L, Lazzeri S.

Eye (Lond). 2014 Apr;28(4):422-9. doi: 10.1038/eye.2013.304. Epub 2014 Jan 17. Erratum in: Eye (Lond). 2014 Apr;28(4):506.

9.

Is it worthwhile to conduct a randomized controlled trial of glaucoma screening in the United Kingdom?

Burr J, Hernández R, Ramsay C, Prior M, Campbell S, Azuara-Blanco A, Campbell M, Francis J, Vale L.

J Health Serv Res Policy. 2014 Jan;19(1):42-51. doi: 10.1177/1355819613499748. Epub 2013 Oct 2.

10.

Why do people present late with advanced glaucoma? A qualitative interview study.

Prior M, Francis JJ, Azuara-Blanco A, Anand N, Burr JM; Glaucoma screening Platform Study group.

Br J Ophthalmol. 2013 Dec;97(12):1574-8. doi: 10.1136/bjophthalmol-2013-303813. Epub 2013 Sep 24.

11.

In vivo optic nerve head biomechanics: performance testing of a three-dimensional tracking algorithm.

Girard MJ, Strouthidis NG, Desjardins A, Mari JM, Ethier CR.

J R Soc Interface. 2013 Jul 24;10(87):20130459. doi: 10.1098/rsif.2013.0459. Print 2013 Oct 6.

12.

Bevacizumab-loaded polyurethane subconjunctival implants: effects on experimental glaucoma filtration surgery.

Paula JS, Ribeiro VR, Chahud F, Cannellini R, Monteiro TC, Gomes EC, Reinach PS, Rodrigues Mde L, Silva-Cunha A.

J Ocul Pharmacol Ther. 2013 Jul-Aug;29(6):566-73. doi: 10.1089/jop.2012.0136. Epub 2013 Feb 7.

13.

Developing the specifications of an open angle glaucoma screening intervention in the United Kingdom: a Delphi approach.

Campbell SE, Azuara-Blanco A, Campbell MK, Francis JJ, Greene AC, Ramsay CR, Burr JM.

BMC Health Serv Res. 2012 Dec 5;12:447. doi: 10.1186/1472-6963-12-447.

14.

Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma.

Roh M, Zhang Y, Murakami Y, Thanos A, Lee SC, Vavvas DG, Benowitz LI, Miller JW.

PLoS One. 2012;7(7):e40065. doi: 10.1371/journal.pone.0040065. Epub 2012 Jul 3.

15.
16.

Effect of Bak Foong Pills on the expression of β-amyloid in rat retina with optic nerve transection.

Zhao TT, Li YQ, Tang LS, Li YH, Fan F, Guo XJ.

Int J Ophthalmol. 2011;4(1):58-61. doi: 10.3980/j.issn.2222-3959.2011.01.13. Epub 2011 Feb 18.

17.

What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities.

Li T, Vedula SS, Scherer R, Dickersin K.

Ann Intern Med. 2012 Mar 6;156(5):367-77. doi: 10.7326/0003-4819-156-5-201203060-00009.

18.

Evidence base for an intervention to maximise uptake of glaucoma testing: a theory-based cross-sectional survey.

Prior M, Burr JM, Ramsay CR, Jenkinson D, Campbell S, Francis JJ; Glaucoma screening Platform Study group.

BMJ Open. 2012 Mar 1;2(2):e000710. doi: 10.1136/bmjopen-2011-000710. Print 2012.

19.

Stem cell therapy for retinal diseases: update.

Siqueira RC.

Stem Cell Res Ther. 2011 Dec 29;2(6):50. doi: 10.1186/scrt91. Review.

20.

Stem cell therapy for glaucoma: possibilities and practicalities.

Johnson TV, Bull ND, Martin KR.

Expert Rev Ophthalmol. 2011 Apr 1;6(2):165-174.

Supplemental Content

Support Center